CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer

British Journal of Cancer

Volumn 101, Issue 11, 2009, Pages 1824-1832

  Van Agthoven, T ^a   Sieuwerts, A M ^a   Veldscholte, J ^a   Meijer Van Gelder, M E ^a   Smid, M ^a   Brinkman, A ^a   Den Dekker, A T ^a   Leroy, I M ^a   Van Ijcken, W F J ^a   Sleijfer, S ^a   Foekens, J A ^a   Dorssers, L C J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Drug resistance; Functional screen; Gene expression profile; Insertion mutagenesis; Prognostic and predictive markers; Tamoxifen

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; MESSENGER RNA; TAMOXIFEN;

ADULT; AGED; ARTICLE; BIOINFORMATICS; BREAST CANCER; BREAST TUMOR; CANCER CELL CULTURE; CANCER GROWTH; CITED2 GENE; DNA MICROARRAY; GENE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LYMPH NODE; MAJOR CLINICAL STUDY; METASTASIS; MUTAGENESIS; NCOR2 GENE; PRIORITY JOURNAL; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NUCLEAR RECEPTOR CO-REPRESSOR 2; RECEPTORS, ESTROGEN; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL RATE; TAMOXIFEN; TRANS-ACTIVATORS;

EID: 70649111220     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605423     Document Type: Article

References (50)

1. Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2:101-112
2. Bai L, Merchant JL (2007) A role for CITED2, a CBP/p300 interacting protein, in colon cancer cell invasion. FEBS Lett 581:5904-5910
3. Bakker WJ, Harris IS, Mak TW (2007) FOXO3a is activated in response to hypoxic stress and inhibits HIF1-induced apoptosis via regulation of CITED2. Mol Cell 28:941-953
4. Brinkman A, Van der Flier S, Kok EM, Dorssers LCJ (2000) BCAR1, a human homologue of the adapter protein p130Cas and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst 92:112-120
5. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22:7316-7339
6. Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R (2008) Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res 68:7493-7501
7. Dorssers LCJ, Van Agthoven T, Brinkman A, Veldscholte J, Smid M, Dechering KJ (2005) Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor pathway. Breast Cancer Res 7:R82-R92
8. Dorssers LCJ, Van Agthoven T, Dekker A, Van Agthoven TLA, Kok EM (1993) Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses:Identification of bcar-1, a common integration site. Mol Endocrinol 7:870-878
9. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials. Lancet 365:1687-1717
10. Edgar R, Domrachev M, Lash AE (2002) Gene expression omnibus:NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30:207-210
11. EORTC Breast Cancer Cooperative Group (2000) Manual for Clinical Research and Treatment in Breast Cancer. pp 116-117. Excerpta Medical:Almere, The Netherlands
12. Foekens JA, Portengen H, van Putten WL, Peters HA, Krijnen HL, Alexieva-Figusch J, Klijn JG (1989) Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res 49:5823-5828
13. Fox SB, Braganca J, Turley H, Campo L, Han C, Gatter KC, Bhattacharya S, Harris AL (2004) CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1alpha. Cancer Res 64:6075-6081
14. Green AR, Burney C, Granger CJ, Paish EC, El-Sheikh S, Rakha EA, Powe DG, Macmillan RD, Ellis IO, Stylianou E (2008) The prognostic significance of steroid receptor co-regulators in breast cancer:co-repressor NCOR2/SMRT is an independent indicator of poor outcome. Breast Cancer Res Treat 110:427-437
15. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer:a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switserland. Cancer 39:1289-1293
16. Howell A (2006) Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr Relat Cancer 13:689-706
17. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll JS (2008) Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456:663-666
18. Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, Tutt AN, Crook T, Lord CJ, Ashworth A (2008) Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13:91-104
19. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN (1995) Use of tamoxifen for breast cancer:Twenty-eight years later. J Clin Oncol 13:513-529
20. Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Portengen H, Dorssers LC, Klijn JG, Berns EM (2005) Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23:732-740
21. Jansen MP, Sieuwerts AM, Look MP, Ritsier K, meijer-Van Gelder ME, van Staveren IL, Klijn JG, Foekens JA, Berns EM (2007) HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer:a retrospective study. J Clin Oncol 25:662-668
22. Jepsen K, Solum D, Zhou T, McEvilly RJ, Kim HJ, Glass CK, Hermanson O, Rosenfeld MG (2007) SMRT-mediated repression of an H3K27 demethylase in progression from neural stem cell to neuron. Nature 450:415-419
23. Jordan VC (1995) Third Annual William L McGuire Memorial Lecture-Studies on the estrogen receptor in breast cancer-20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 36:267-285
24. Kleinschmidt MA, Streubel G, Samans B, Krause M, Bauer UM (2008) The protein arginine methyltransferases CARM1 and PRMT1 cooperate in gene regulation. Nucleic Acids Res 36:3202-3213
25. Korf U, Henjes F, Schmidt C, Tresch A, Mannsperger H, Lobke C, Beissbarth T, Poustka A (2008) Antibody microarrays as an experimental platform for the analysis of signal transduction networks. Adv Biochem Eng Biotechnol 110:153-175
26. Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, Portengen H, Meijer-Van Gelder ME, Piepenbrock C, Olek A, Hofler H, Kiechle M, Klijn JG, Schmitt M, Maier S, Foekens JA (2005) Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 65:4101-4117
27. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of NCIEWGoCD (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229-235 (Pubitemid 44631925)
28. Meester-Smoor MA, Janssen MJ, Grosveld GC, de Klein A, van IWF, Douben H, Zwarthoff EC (2008) MN1 affects expression of genes involved in hematopoiesis and can enhance as well as inhibit RAR/RXR-induced gene expression. Carcinogenesis 29:2025-2034
29. Meijer D, Jansen MPHM, Look MP, Ruigrok-Ritstier K, Van Staveren IL, Sieuwerts AM, Van Agthoven T, Foekens JA, Dorssers LCJ, Berns EMJJ (2009) TSC22D1 and PSAP predict clinican outcome of tamoxifen treatment in patients with recurrent breast cancer. Breast Cancer Res Treat 113:253-260
30. Meijer D, Sieuwerts AM, Look MP, Van Agthoven T, Foekens JA, Dorssers LCJ (2008) Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. Endocr Relat Cancer 15:101-111
31. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmeno-pausal women:analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101-2109
32. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in post-menopausal women:results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18:3758-3767 (Pubitemid 30846221)
33. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618
34. Osborne CK, Shou J, Massarweh S, Schiff R (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11:865s-870s (Pubitemid 40111098)
35. Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, Biganzoli L, Cufer T, Duchateau L, Hamilton A, Lobelle JP, Piccart M (2003) Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14:1391-1398
36. Perissi V, Rosenfeld MG (2005) Controlling nuclear receptors:the circular logic of cofactor cycles. Nat Rev Mol Cell Biol 6:542-554
37. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747-752
38. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH (2007) Pathways to tamoxifen resistance. Cancer Lett 256:1-24
39. Schuchardt S, Borlak J (2008) Quantitative mass spectrometry to investigate epidermal growth factor receptor phosphorylation dynamics. Mass Spectrom Rev 27:51-65
40. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R (2004) Mechanisms of tamoxifen resistance:increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926-935
41. Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, de Weerd V, Portengen H, Klijn JG, Foekens JA (2006) Which cyclin E prevails as prognostic marker for breast cancer Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res 12:3319-3328
42. Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, Portengen H, Klijn JG, Foekens JA (2005) How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer:a retrospective study. Clin Cancer Res 11:7311-7321
43. Sieuwerts AM, Usher PA, Meijer-van Gelder ME, Timmermans M, Martens JW, Brunner N, Klijn JG, Offenberg H, Foekens JA (2007) Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. Clin Chem 53:1280-1288
44. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW (2008) Subtypes of breast cancer show preferential site of relapse. Cancer Res 68:3108-3114
45. Speer R, Wulfkuhle J, Espina V, Aurajo R, Edmiston KH, Liotta LA, Petricoin III EF (2008) Molecular network analysis using reverse phase protein microarrays for patient tailored therapy. Adv Exp Med Biol 610:177-186
46. Van Agthoven T, Sieuwerts AM, Meijer-Van Gelder ME, Look MP, Smid M, Veldscholte J, Sleijfer S, Foekens JA, Dorssers LCJ (2009a) Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol 27:542-549
47. Van Agthoven T, Van Agthoven TLA, Dekker A, Van der Spek PJ, Vreede L, Dorssers LCJ (1998) Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J 17:2799-2808
48. Van Agthoven T, Veldscholte J, Smid M, Van Agthoven TLA, Vreede L, Broertjes M, De Vries I, De Jong D, Sarwari R, Dorssers LCJ (2009b) Functional screen identifies genes associated with human breast cancer progression. Breast Cancer Res Treat 114:23-30
49. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679
50. Yanagie H, Hisa T, Ogata A, Miyazaki A, Nonaka Y, Nishihira T, Osada I, Sairennji T, Sugiyama H, Furuya Y, Kidani Y, Takamoto S, Takahashi H, Eriguchi M (2009) Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro. Biomed Pharmacother 63(8):553-560